Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results

OBJECTIVES: SB2 is a biosimilar to the reference infliximab (INF). Similar efficacy, safety and immunogenicity between SB2 and INF up to 30 weeks were previously reported. This report investigates such clinical similarity up to 54 weeks, including structural joint damage. METHODS: In this phase III,...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S., Choe, Jung-Yoon, Prodanovic, Nenad, Niebrzydowski, Jaroslaw, Staykov, Ivan, Dokoupilova, Eva, Baranauskaite, Asta, Yatsyshyn, Roman, Mekic, Mevludin, Porawska, Wieskawa, Ciferska, Hana, Jedrychowicz-Rosiak, Krystyna, Zielinska, Agnieszka, Choi, Jasmine, Rho, Young Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850768/
https://www.ncbi.nlm.nih.gov/pubmed/28957563
http://dx.doi.org/10.1093/rheumatology/kex254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850768/
https://www.ncbi.nlm.nih.gov/pubmed/28957563
http://dx.doi.org/10.1093/rheumatology/kex254

Ejemplares similares